G
Gary D. Tollefson
Researcher at Eli Lilly and Company
Publications - 218
Citations - 17672
Gary D. Tollefson is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Olanzapine & Placebo. The author has an hindex of 64, co-authored 218 publications receiving 17230 citations. Previous affiliations of Gary D. Tollefson include Indiana University.
Papers
More filters
Journal ArticleDOI
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
Gary D. Tollefson,Charles M. Beasley,Pierre V. Tran,J.S. Street,John A. Krueger,Roy N. Tamura,Karin A. Graffeo,Martha E. Thieme +7 more
TL;DR: Olanzapine shows a superior and broader spectrum of efficacy in the treatment of schizophrenic psychopathology, with a substantially more favorable safety profile, than haloperidol and meets several of the criteria for a novel atypical antipsychotic agent.
Journal ArticleDOI
Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression
Mauricio Tohen,Mauricio Tohen,Eduard Vieta,Joseph R. Calabrese,Terence A. Ketter,Gary S. Sachs,Charles L. Bowden,Philip B. Mitchell,Franca Centorrino,R.C. Risser,Robert W. Baker,Angela R. Evans,Karin Beymer,Sanjay Dubé,Sanjay Dubé,Gary D. Tollefson,Alan Breier +16 more
TL;DR: Olanzapine is more effective than placebo, and combined olanzapine-fluoxetine isMore effective than olanZapine and placebo in the treatment of bipolar I depression without increased risk of developing manic symptoms.
Journal ArticleDOI
Antipsychotic drug effects on brain morphology in first-episode psychosis
Jeffrey A. Lieberman,Jeffrey A. Lieberman,Gary D. Tollefson,Cecil Charles,Robert B. Zipursky,Tonmoy Sharma,René S. Kahn,Richard S.E. Keefe,Alan I. Green,Raquel E. Gur,Joseph P. McEvoy,Diana O. Perkins,Robert M. Hamer,Hongbin Gu,Mauricio Tohen,Mauricio Tohen +15 more
TL;DR: In this article, the authors found that olanzapine-treated patients have less change over time in whole brain gray matter volumes and lateral ventricle volumes than haloperidol-treatment patients and that gray matter changes are associated with changes in psychopathology and neurocognition.
Journal ArticleDOI
Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial
Charles M. Beasley,Gary D. Tollefson,Pierre Tran,Winston Satterlee,Todd M. Sanger,Susan H. Hamilton +5 more
TL;DR: The most common treatment-emergent adverse events included somnolence, agitation, asthenia, and nervousness.
Journal ArticleDOI
Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.
Pierre V. Tran,S.H. Hamilton,Amy J. Kuntz,Janet H. Potvin,Scott W. Andersen,Charles Jr Beasley,Gary D. Tollefson +6 more
TL;DR: Olanzapine seemed to have a risk-versus-benefit advantage in the management of psychotic symptoms, and the differential preclinical profiles of these two drugs were also evident in a controlled, clinical investigation.